Market Overview:
The global multiple sclerosis therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of multiple sclerosis, rising awareness about available treatment options, and technological advancements in the field of MS therapeutics. The beta interferon segment is expected to dominate the global MS therapeutics market during the forecast period, owing to its high efficacy and safety profile. The monoclonal antibodies segment is also anticipated to witness significant growth during the forecast period, due to increasing R&D investments in this area. In terms of application, hospital pharmacies are expected to account for a major share of the global MS therapeutics market during the forecast period. This can be attributedtothe growing numberofMS patients seeking treatment in hospitals and rising demand for expensive therapies such as monoclonal antibodies and antineoplastic agents.
Product Definition:
Multiple sclerosis therapeutics are drugs or other treatments used to manage the symptoms of multiple sclerosis (MS), a chronic, progressive neurological disorder. MS is caused by damage to the myelin sheath, the protective covering that surrounds nerve cells in the brain and spinal cord. This damage disrupts communication between the brain and body, leading to a wide range of symptoms, including muscle weakness, numbness or tingling sensations, vision problems, difficulty with balance and coordination, bladder problems, and cognitive changes.
There is no cure for MS currently available; however various therapies are available that can help reduce symptoms and improve quality of life for people living with MS. These include medication such as disease-modifying drugs (DMDs) which slow down progression of the disease; symptomatic medications such as antidepressants or anticonvulsants which can help relieve specific symptoms; physical therapy to improve mobility and strength; occupational therapy to help adapt daily activities; speech therapy if difficulties with swallowing or speaking occur; and nutritional counseling.
Beta Interferon:
Beta interferon, also known as Betaferon, is a medication used to treat multiple sclerosis. It is given by injection into the muscle as it is not absorbed by the blood stream. The drug was approved in 1995 in Japan and 1996 in Europe and U.S., where it has been widely used ever since due to its efficiency over other treatments for multiple sclerosis such as plaquenil or Avonex (Dextromethorphan/quinine).
Corticosteroids:
Corticosteroids are a group of prescription drugs that reduce inflammation by decreasing the production of cytokines. Corticosteroids are used in multiple sclerosis therapeutics for two main reasons, to decrease myeloid cell infiltration into the central nervous system (CNS) and to limit further damage to the oligodendrocyte layer present in the brain.
Application Insights:
The hospital pharmacies segment dominated the market in 2017 and is expected to maintain its lead over the forecast period. This can be attributed to factors such as presence of a large patient base with multiple sclerosis, increasing awareness about availability of therapies through hospital pharmacies, and growing emphasis on cost-effectiveness.
The retail pharmacy segment is also anticipated to witness lucrative growth during the forecast period owing to increase in prevalence of multiple sclerosis among consumers aged 40 years and above coupled with high demand for low-cost drugs. Moreover, e-commerce distribution channels are expected to open up new avenues for Multiple Sclerosis Therapeutics Market growth over the coming years due largely on increased product penetration owing to favorable government regulations regarding online healthcare sales.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players, high disease prevalence, and availability of effective treatment methods are some factors attributing to its largest share. In addition, increasing healthcare expenditure and rising awareness about multiple sclerosis among people are expected to drive growth during the forecast period.
Asia Pacific is estimated to be the fastest-growing region over the forecast period owing to an increase in disposable income along with rise in consumer awareness regarding multiple sclerosis treatment options. Moreover, growing penetration of retail pharmacies due to regulatory support for generic drugs will propel market growth during this period as these pharmacies cater primarily to low-income groups thus promoting access irrespective of socioeconomic status which is contrary for branded products where branded by prescription only medicine sold by hospital pharmacies or online from e-commerce websites after approval by doctor only basis).
Growth Factors:
- Increasing incidence of multiple sclerosis (MS) across the globe
- Growing awareness about MS and its treatment options
- Rising demand for novel and effective MS therapies
- Availability of government funding for MS research and development
- Technological advancements in MS therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Multiple Sclerosis Therapeutics Market Research Report
By Type
Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, Others
By Application
Hospital Pharmacies, Retail Pharmacies, e-Commerce
By Companies
Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck, AbbVie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
225
Number of Tables & Figures
158
Customization Available
Yes, the report can be customized as per your need.
Global Multiple Sclerosis Therapeutics Market Report Segments:
The global Multiple Sclerosis Therapeutics market is segmented on the basis of:
Types
Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, e-Commerce
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Teva Pharmaceuticals
- Sanofi Genzyme
- Bayer
- Pfizer
- Biogen Idec
- Merck
- AbbVie
Highlights of The Multiple Sclerosis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Multiple Sclerosis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Multiple sclerosis (MS) is a chronic, disabling disease of the central nervous system. MS is caused by damage to the myelin sheath that covers nerve cells in the brain and spinal cord. This damage can lead to problems with movement, communication, and thinking. There is no cure for MS, but there are treatments that can help manage symptoms. Multiple sclerosis therapies include medications to reduce inflammation and improve nerve function; surgery to remove or repair damaged tissue; and physical therapy to help people with MS regain mobility and strength.
Some of the key players operating in the multiple sclerosis therapeutics market are Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck, AbbVie.
The multiple sclerosis therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Multiple Sclerosis Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Multiple Sclerosis Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Multiple Sclerosis Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Multiple Sclerosis Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Multiple Sclerosis Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Multiple Sclerosis Therapeutics Market Size and Y-o-Y Growth
4.5.2 Multiple Sclerosis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Beta Interferon
5.2.2 Corticosteroids
5.2.3 Monoclonal Antibodies
5.2.4 Antineoplastic Agents
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 e-Commerce
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Multiple Sclerosis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Multiple Sclerosis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Beta Interferon
9.6.2 Corticosteroids
9.6.3 Monoclonal Antibodies
9.6.4 Antineoplastic Agents
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 e-Commerce
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Beta Interferon
10.6.2 Corticosteroids
10.6.3 Monoclonal Antibodies
10.6.4 Antineoplastic Agents
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 e-Commerce
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Beta Interferon
11.6.2 Corticosteroids
11.6.3 Monoclonal Antibodies
11.6.4 Antineoplastic Agents
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 e-Commerce
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Beta Interferon
12.6.2 Corticosteroids
12.6.3 Monoclonal Antibodies
12.6.4 Antineoplastic Agents
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 e-Commerce
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Beta Interferon
13.6.2 Corticosteroids
13.6.3 Monoclonal Antibodies
13.6.4 Antineoplastic Agents
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 e-Commerce
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Multiple Sclerosis Therapeutics Market: Competitive Dashboard
14.2 Global Multiple Sclerosis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Teva Pharmaceuticals
14.3.3 Sanofi Genzyme
14.3.4 Bayer
14.3.5 Pfizer
14.3.6 Biogen Idec
14.3.7 Merck
14.3.8 AbbVie
